• The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
• /
• v.22 no.1
• /
• pp.172-180
• /
• 2009

Objective : to investigate the modalities and treatments with atopic dermatitis. Methods : We made up a questionnaire consisting of symptoms, birth, family history, previous treatments of atopic dermatitis. We interviewed mild to severe 60 atopic dermatitis patients with questionnaire, from August to October, 2008 who were participating in clinical trials of Kyunghee University East-west neo medical center. Results : The results obtained are summarized as follows: 1. 49(81.7%) out of 60 patients reported previous or current use of medical treatment, and most common type of medical treatment was topical corticosteroid (95.9%). Oral antihistamine (61.2%), oral corticosteroid (61.2%) were also commonly used. 2. 31(51.7%) out of 60 patients reported previous or current use of oriental medical treatment, and most common type of oriental medical treatment was herbal medicine(100%). Acupuncture (41.9%), Herbal external supplements (22.6%) were also used. 3. 36(60.11% ) out of 60 patients reported previous or current use of folk remedies, and the most common type of folk remedy was extract of tree(Mokcho-ak)(75.0%). Aloe(61.1%), Charcoal(22.2%) were also commonly used. Conclusion : It seems the frequency of folk remedies used were related to severity of AD. However, there were no significant difference between medical treatment and oriental medical treatment.

• Korean Journal of Clinical Pharmacy
• /
• v.30 no.4
• /
• pp.264-269
• /
• 2020

Background: Inflammatory diseases can increase the prevalence of anemia. Recent studies confirmed that the prevalence of anemia is increased by atopic dermatitis (AD), a chronic inflammatory disease. Therefore, we aimed to elucidate the correlation between AD severity and prevalence of anemia. Methods: We used data of pediatric patients from the Health Insurance Review and Assessment Service (HIRA-PPS-2016). We included pediatric patients (<18 years) with AD diagnosis who were prescribed medications for AD. We applied a propensity score method with inverse probability of treatment weighting (IPTW) adjusting for differences in prevalence of confounders and performed IPTW logistic regression to evaluate associations between the anemia and severity of AD. Results: In total, 91,501 patients (mild AD: 47,054 patients; moderate-to-severe AD: 44,447 patients) <18 years who were prescribed drugs for AD were analyzed. Analysis of the probability of patients with mild AD and prevalence of anemia as a reference revealed an odds ratio (OR) of 1.159 (95% CI, 1.109-1.212; p<0.001) in moderate-to-severe AD patients, indicating a correlation between anemia prevalence and AD severity. Subgroup analysis according to gender, age group, and type of health insurance revealed there was an association between AD severity and anemia except in patients equal or older than 7 years. Conclusion: The prevalence of anemia increased with AD severity despite adjusting for confounding factors. Our results support the hypothesis that AD can cause anemia, and anemia prevalence could be increased in severe AD patients. Further studies are needed to establish a pathological basis.

• The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
• /
• v.28 no.1
• /
• pp.85-99
• /
• 2015

Objective : The purpose of this study is to report the effectiveness of a long-term Korean Medicine Treatment on 1035 atopic dermatitis patients Methods : Objective SCORAD Index(OSI) is used for measuring the degree of atopic dermatitis with photos of total 1035 atopic dermatitis patients who has visited oriental clinic from January 9, 2011 to October 31, 2013. Then, OSI was estimated according to gender, age, period of treatment and intensity. Results : 1. The ratio of male to female was 44.4 : 55.6. All patients were constituted with 26.5% of 0~11 year-old group, 15.7% of 12~18 year-old and 57.9% of 19 and more year-old. 2. The ratio of OSI improvement was significantly higher in women than in men after 3 month treatment, but there was no significant difference after 6, 9 and 12 months. 3. The OSI improvement of 0~11 year-old group was significantly higher than the other groups after 3 month treatment. But at the other periods of treatment, there was no significantly difference of the improvement among 3 different groups of age. 4. After 3, 6, 9 and 12 month treatment, the score of OSI was significantly lower than before treatment. After 12 month treatment, the score of OSI was lowest compared to the other periods of treatment. 5. The final OSI score of 87.7% patients was decreased compared to the initial. 6. All patients had been divided with 1.93% of the mild, 22.7% of the moderate and 75.4% of the severe by OSI intensity at initial visit. At final visit, the composition of patients was changed to 14.6% of the mild, 53.7% of the moderate and 31.7% of the severe. 7. The mild patients had got 42.56% of OSI improvement at the final. And the moderate had got 37.72% of OSI improvement at the final. 8. The severe patients had got 36.76% of OSI improvement at the final. And 89.2% of the severe had got decreased final OSI score compared to the initial. Conclusion : There was a definite decreasing of OSI score on the significant rate of Atopic dermatitis patients who had been treated by Korean medicine treatment at least for 3 months.

• Korean Journal of Food Science and Technology
• /
• v.53 no.2
• /
• pp.139-148
• /
• 2021

Atopic dermatitis is a chronic, recurrent, inflammatory skin disease that is a well-known allergic disease with severe itching, making daily life difficult. Since the immunomodulatory action of vitamin D has been reported, several researchers have attempted to determine the correlation between vitamin D and atopic dermatitis. In this review, 41 articles meeting the inclusion criteria were selected and reviewed from the articles published to date. Several studies have reported that low vitamin D levels are associated with the onset of atopic dermatitis and severe atopic dermatitis, but the opinions remain conflicting. Similarly, there are conflicting opinions on the improvement effect of oral vitamin D supplementation on atopic dermatitis, but some possibilities have been suggested. To apply vitamin D as a therapeutic agent for atopic dermatitis, a more systematically designed experiment should be conducted, and an appropriate intake dose for an immunomodulatory function should be obtained.

• The Journal of Korean Medicine
• /
• v.29 no.1
• /
• pp.179-191
• /
• 2008

Background and Objectives : Atopic dermatitis is a recurrent or chronic eczematous skin disease with severe pruritus,and has increased in Korea. Although the pathogenic mechanisms of atopic dermatitis are yet unknown, recently skin barrier dysfunction and hyperresponsive Th2 cells in the acute phase have been reported as important mechanisms. Cheonggi-san(CGS) is used in oriental clinics for treatingacute skin lesions of eczema or urticaria. There have been no studies on the therapeutic mechanism of CGS for curing atopic dermatitis. We aimed to find out the therapeutic effects of its internaluse on atopic dermatitis-like skin lesions, induced in NC/Nga mice by the mite antigen D. pteronyssinus and disrupting skin barrier. Materials and Methods : The NC/Nga mice were classified into three groups: control group, atopic dermatitis elicitated group(AD), and CGS treated group (CT). Atopic dermatitis-like skin lesions were induced on the back of female NC/Nga mice, 12 weeks of age, by tape stripping, 5% SDS applied to disrupt skin barrier and painting 3 times a week with D. pteronyssinus crude extract solution for 3 weeks. CT was treated with CGS orally after atopic dermatitis was elicitated. We observed changes of skin damage, mast cells, substance P, angiogenesis, skin barrier, Th2 cell differentiation, nuclear factor-${\kappa}B(NF-{\kappa}B)$ p65 activation and COX-2 in NC/Nga mice with atopic dermatitis-like skin lesions. Results : The skin damages as eczema were seenin AD, but mitigated in CT. The degranulated mast cells in dermal papillae increased in AD, but decreased in CT. The substance P positive reacted cells in CT remarkably decreased. The angiogenesis increased in AD, but decreased in CT. The decrease of lipid deposition and ceramide in AD was seen, but anincrease of lipid deposition and ceramide in CT was seen. The distribution of IL-4 positive reacted cells in dermal papillae increased in AD, but decreased in CT. The distribution of NF-${\kappa}B$ p65 positive reacted cells & COX-2 positive reacted cells in CT decreased. Conclusion : The results may suggest that the CGS per os decreases the dysfunction of the skin barrier, inhibits Th2 cell differentiation and inhibits NF-${\kappa}B$ p65 activation in NC/Nga mice with atopic dermatitis-like skin lesions.

• Korean Journal of Psychosomatic Medicine
• /
• v.14 no.2
• /
• pp.88-93
• /
• 2006

Objective : The aim of this study was to examine the relationship between IgE-mediated atopic dermatitis and attention deficit hyperactivity disorder(ADHD) in Korean children. Method : This case-control study included 69 patients with atopic dermatitis and 42 normal students. Diagnoses of atopic dermatitis and assessments of its severity were made by the dermatologist. The MAST tests were administered to atopic dermatitis patients. The parents of all of the subjects completed the parent versions of the ADHD Rating Scale-IV(ARS). Results: Compared to the normal control group, the atopic dermatitis group scored significantly higher in the total, inattention, and hyperactivity/impulsivity profiles of the ARS(t=3.35, p<0.01 : t=6.41, p<0.01 ; t=3.93, p<0.01, respectively), The atopic dermatitis patients with ADHD hyperactivity/impulsivity subtype showed more severe symptoms of atopic dermatitis than those with ADHD inattentive subtype. The MAST-positive atopic dermatitis patients showed significantly increased incidence of ADHD symptoms than the MAST-negative counterparts. Conclusion : The results of this study suggest the possibility of an association between IgE-mediated atopic responsiveness and ADHD symptomatology.

• 대한상한금궤의학회지
• /
• v.5 no.1
• /
• pp.85-92
• /
• 2013

Objective : This case report aims to show the effect of Osuyu-tang on an atopic dermatitis. The patient was diagnosed with Yangmyung-byung based on Shanghanlun provisions. Methods : According to Diagnostic system based on Shanghanlun provisions, the patient was diagnosed with Yanamyung-byung and has been unusual dietary habits. So she took Osuyu-tang decoction for 2 weeks. We evaluated the results of treatment by SCORAD Index and before and after treatment photos. Results : After taking Osuyu-tang decoction for 2weeks, the patient's SCORAD INDEX and symptoms was decreased from 49.5(severe) to 3.5(mile). Also, the patient's chronic diagestive disorder improved. Conclusions : This case report showed an effectiveness of using Osuyu-tang according to Diagnostic system based on Shanghanlun provisions on atopic dermatitis.

• Allergy, Asthma & Respiratory Disease
• /
• v.12 no.2
• /
• pp.58-71
• /
• 2024

Atopic dermatitis (AD) is the most prevalent inflammatory skin condition, with approximately 80% of cases originating in childhood and some emerging in adulthood. In South Korea, the estimated prevalence of AD ranges between 10% and 20% in children and 1% and 3% in adults. Severe/recalcitrant AD manifests as a chronic, relapsing skin disorder, persisting with uncontrolled symptoms even after topical steroid treatment. Corticosteroids and systemic immunosuppression, conventionally the standard care for difficult-to-treat diseases, cause numerous undesirable side effects. When AD persists despite topical steroid application, systemic therapies like cyclosporine or systemic steroids become the second treatment strategy. The desire for targeted treatments, along with an enhanced understanding of AD's pathophysiology, has spurred novel therapeutic development. Recent advances introduce novel systemic options, such as biological agents and small-molecule therapy, tailored to treat severe or recalcitrant AD. Notably, dupilumab, a monoclonal antibody inhibiting interleukin 4 and 13, marked a transformative breakthrough upon gaining approval from the U.S. Food and Drug Administration (FDA) in 2017, leading to a paradigm shift in the systemic treatment of AD. Furthermore, both dupilumab and Janus kinase inhibitors, including baricitinib, abrocitinib, and tofacitinib, now approved by the Korean FDA, have established their applicability in clinical practice. These innovative therapeutic agents have demonstrated favorable clinical outcomes, effectively addressing moderate to severe AD with fewer side reactions than those associated with previous systemic immunosuppressants. This review summarizes the latest advancements and evidence regarding systemic treatments for AD, including newly approved drugs in Korea.

• The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
• /
• v.30 no.1
• /
• pp.10-16
• /
• 2017

Objectives : Atopic Dermatitis is a recurrent, chronic, allergic eczema with severe itching sensation. This study designed to research Sihocheonggan-tang & Sihocheonggan-san to find out treatability for atopic dermatitis. Methods : We got 14 search results with searching word '시호청간탕', '시호청간산' in 'OASIS', 'NDSL', 'RISS'. We classified these studies according to the type of study, diseases, treatment methods and treatment outcomes. Results : In the analysis of the diseases, Sihocheonggan-tang & Sihocheonggan-san was given for Eczema nummulare, Ermatitis seborrheica, Erythema multiforme, Eczema and Atopic dermatitis. In the analysis of the treatment methodes, the dosage form of Sihocheonggan-tang & Sihocheonggan-san was herbal medication, pill, granules and herbal medication & pill. In the analysis of the treatment outcomes, the symptoms of all patients were improved. In the experimental researches, it was proved that Sihocheonggan-tang & Sihocheonggan-san has effects that affect anti-inflammatory, skin protection and recovery of keratinocyte. Conclusions : For this study, we can consider Sihocheonggan-tang & Sihocheonggan-san is effective for atopic deramatitis. So, it is necessary to carry out clinical trial for Sihocheonggan-tang & Sihocheonggan-san in atopic dermatitis to evaluate safety and efficacy.

• Korean Journal of Veterinary Service
• /
• v.47 no.1
• /
• pp.19-26
• /
• 2024

Canine atopic dermatitis (CAD) is an inflammatory and pruritic skin disease with a genetic predisposition, characterized by allergic sensitivity. It is known for its distinctive clinical features, including a high recurrence rate and chronic progression. To manage CAD, medications such as steroids and immunosuppressants are commonly used, but consideration should be given to the potential resistance and side effects associated with long-term use. In order to reduce these risks, various adjunctive factors are currently under consideration. One of these adjunctive agents, probiotics have shown effectiveness in regulating atopic dermatitis by modulating immune responses, as demonstrated in several recent studies. In this study, a substance combining three probiotics-L. plantarum, L. reuteri, and Ped. Acidilactici-was used in patients diagnosed with CAD, and its clinical effects and safety were evaluated. The trial involved four groups: a group receiving conventional treatment for atopic dermatitis (A), a group prescribed low-dose probiotics (B), a group prescribed high-dose probiotics (C), and a group prescribed topical probiotics (D). For assessment, the Canine Atopic Dermatitis Extent and Severity Index (CADESI), Trans-Epidermal Water Loss (TEWL) test, gut microbiome, and serum IgE test were conducted. As a result, the CAD severity index (CADESI-4) significantly decreased in the probiotics groups (B & C). In the serum total IgE test, the groups consuming probiotics showed a significant difference, while the group using topical probiotics (D) did not exhibit a significant change. Also, the TEWL test showed improved scores in the probiotics groups (B & C). Therefore, L. plantarum, L. reuteri, and Ped. Acidilactici probiotic combination could be considered as an effective adjunctive treatment, especially for atopic patients with moderate to severe skin lesions.